Deutsche Bank Shifts Novartis From Hold to Sell in Q3 Review

Enna Lee

1 min read

Add as a preferred source on Google

Deutsche Bank Shifts Novartis From Hold to Sell in Q3 Review

The downgrade came as the bank reviewed Novartis’ third-quarter 2026 results.

By Enna Lee

Published Oct 30, 2026, 3:30 PM EDT

An empty blister pocket casts a shadow over the remaining tablets / TokenPost.ai

Deutsche Bank shifted its Novartis recommendation to Sell, replacing Hold, on Friday, Oct. 30, as it reviewed the Swiss drugmaker’s third-quarter 2026 results.

The rating decision was part of Deutsche Bank’s review of the company’s Q3 results.

Enna Lee

Reporter

Enna Lee reports on investing and digital-asset markets for TokenPost. Send corrections or tips to info@tokenpost.com.